Cefepime/tazobactam

头孢吡肟/他唑巴坦

Report date: 2022/12/06 20:00:40
QIDP

Base Information

Drug NameCefepime/tazobactam
Drug Alias Nametazobactam/Cefepime盐酸头孢吡肟/他唑巴坦钠盐酸头孢吡肟+他唑巴坦钠Cefepime Hydrochloride/Tazobactam Sodium他唑巴坦/头孢吡肟 +[11] 
ClassificationSmall molecules > Heterocyclic drugs > Antibiotics > β-lactam antibiotics > Cephalosporins antibiotics
Mechanisms of ActionBeta Lactamase inhibitorsBacterial penicillin-binding protein inhibitorsCell wall inhibitors
TargetsBeta LactamaseBacterial penicillin-binding protein
Therapy Area/IndicationsDrug-Related Side Effects and Adverse ReactionsPyelonephritisUrinary Tract Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsYes Cefepime HydrochlorideTazobactam Sodium
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesWockhardt Bio Ag
China Registration ClassN/A

Develop Information

Active CompaniesWockhardt Ltd
Inactive CompaniesN/A
Active IndicationsPyelonephritisUrinary Tract Infections
Inactive IndicationsDrug-Related Side Effects and Adverse Reactions

Other Information

ATC CodeN/A
Related LinksN/A